Navigation Links
Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
Date:8/24/2011

ANAHEIM, Calif., Aug. 24, 2011 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the following investor conferences in early September:  

  • The Morgan Stanley Global Healthcare Conference at the Grand Hyatt in New York City.  Don M. Bailey, President and Chief Executive Officer, is scheduled to provide an overview of the Company on Wednesday, September 14, 2011 at 8:00 a.m. ET.  Presentations at this conference are not available by webcast.
  • UBS Global Life Sciences Conference at the Grand Hyatt in New York City.  Mr. Bailey is scheduled to present on Monday, September 19, 2011 at 10:30 a.m. ET.  A live webcast and subsequent archived replay of the presentation will be accessible at www.questcor.com, in the "Investor Relations" section under "Events & Presentations."

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus."  Questcor is also exploring the use of Acthar to treat systemic lupus erythematosus, for which Acthar is approved as both a maintenance therapy and to treat exacerbations.  Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need.  For more information, please visit www.questcor.com.


'/>"/>
SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Questcor Announces Third Quarter 2010 Earnings Release Date and Conference Call
2. Questcor Pharmaceuticals to Be Added to S&P SmallCap 600 Index
3. Questcor Pharmaceuticals to Present at the Jefferies Global Healthcare Conference on June 9, 2011
4. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
5. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
8. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
9. VIA Pharmaceuticals to Present at Fourth Annual Noble Financial Equity Conference
10. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman
11. Access Pharmaceuticals to Present at the Noble Financial Equity Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... 2017 , ... NextSteps 2017, NetDimensions’ annual global user conference, ... May on the following dates: , ?    London, UK from May 10-11, ?    New Orleans, ... Performance Institute will be the opening keynote speaker at the NextSteps EMEA ...
(Date:4/26/2017)... HATFIELD, Pa. , April 26, 2017 /PRNewswire/ ... drug delivery platform, has signed a collaborative and ... through Dr. Silvia Muro . The overall ... pharmacokinetics and pharmacodynamics of various 3DNA designs and ... aims involve targeting diseases of the vasculature as ...
(Date:4/25/2017)... California (PRWEB) , ... April 25, 2017 , ... ... Intelligence (AI), leading supplier of Common Lisp (CL) development tools, and market leader ... , which includes key performance enhancements now available within the most effective system ...
(Date:4/25/2017)... , April 25, 2017 ... has licensed its novel immune-modulating technology to an undisclosed ... and allergy. Tregitopes, pronounced T·rej·itopes, are ... immunoglobulin by EpiVax CEO Annie De Groot ... intravenous immunoglobulin G, an autoimmune disease therapy, Tregitopes ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/20/2017)... March 20, 2017 PMD Healthcare announces the ... and Wellness Management System (WMS), a remote, real-time lung ... 2010, PMD Healthcare is a Medical Device, Digital Health, ... dedicated to creating innovative solutions that empower people to ... intent focus, PMD developed the first ever personal spirometer, ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today ... to uncover insights to support its reporting, help direct future ... UK,s leading youth charity will be using Brandwatch Analytics social listening ... better understanding of the topics and issues that are a priority ... ...
Breaking Biology News(10 mins):